eligibility_summary
Eligible: BASECAMP‑1 with HLA‑A02 LOH (NGS), apheresis/PBMC stored cells, unresectable/recurrent advanced/metastatic CRC, NSCLC, PANC, OVCA, MESO or other MSLN+ solid tumor, measurable lesion >1 cm, prior tx, adequate organs, ECOG 0–1, life ≥3 mo. Exclude: curative/SOC tx candidates, prior allo SCT/solid organ tx, MESO pleura→peritoneum, recent cancer therapy/RT, major CV dz, recent PE/DVT, ILD/pneumonitis needing steroids, home O2, pregnant/breastfeeding, no contraception.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06051695 tests A2B694, an autologous, gene‑modified logic‑gated Tmod CAR T-cell therapy, after lymphodepletion. A companion investigational diagnostic (xT CDx with HLA‑LOH assay) confirms tumor HLA‑A02 loss. Mechanism: dual-receptor CAR T with an MSLN-targeting activator and an HLA‑A02–specific inhibitory “blocker,” creating an AND‑NOT gate—T cells kill only cells that are MSLN+ and have lost HLA‑A02, aiming to spare normal MSLN+ tissues that retain HLA‑A02. Targets: mesothelin-expressing solid tumors (CRC, pancreatic, NSCLC, ovarian, mesothelioma, others) with HLA‑A02 loss of heterozygosity. Pathways/cells engaged: redirected autologous T‑cell cytotoxicity (perforin/granzyme, cytokine signaling) against MSLN+ cancer cells, exploitation of HLA class I LOH for tumor specificity.